Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 12/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.51 |
| ▸ | HTR3B | O95264 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557226 | 0.85 | USP2 (0.54) | USP2HTR6ADRB1HTR3EHTR3B | |
| SCHEMBL2851556 | 0.82 | NCF1 (0.46) | HTR6HTR7HTTNCF1 | |
| Caldaret SCHEMBL1650574 | 0.82 | ALDH1A1 (0.52) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL10704299 | 0.82 | HTR6 (0.50) | HTR6THRBHTR2CHTT | |
| Caldaret SCHEMBL3135751 | 0.81 | ALDH1A1 (0.51) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| Caldaret SCHEMBL2853338 | 0.81 | ALDH1A1 (0.51) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| Caldaret SCHEMBL29711318 | 0.81 | ALDH1A1 (0.51) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| Caldaret SCHEMBL3139412 | 0.81 | ALDH1A1 (0.51) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL2857961 | 0.78 | ADRB2 (0.49) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL2848670 | 0.78 | HTR6 (0.52) | HTR6HTR1AHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100486574-C | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2009-05-13 | — | — | CN | claimed |
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | SATOU NAOYA | 2008-05-15 | — | — | US | claimed |
| US-20070270409-A1 | Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-22 | — | — | US | claimed |
| CN-1946396-A | Medicine for prevention and/or treatment of ischemic circulatory disease | MITSUBISHI PHARMA CORP (JP) | 2007-04-11 | — | — | CN | claimed |
| EP-1723955-A1 | MEDICINE FOR PREVENTION AND/OR TREATMENT OF ISCHEMIC CIRCULATORY DISEASE | Mitsubishi Pharma Corporation (JP) | 2006-11-22 | — | — | EP | claimed |
| US-20060167013-A1 | Inhibitors for excessive accumulation of sodium ion in cells | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-07-27 | — | — | US | claimed |
| CN-1638773-A | Pharmaceutical preparation containing aminobenzenesulfonic acid derivative as active ingredient | MITSUBISHI PHARMA CORP (JP) | 2005-07-13 | — | — | CN | claimed |
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-09 | — | — | US | claimed |
| US-20050004139-A1 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient | MITSUBISHI PHARMA CORPORATION (JP) | 2005-01-06 | — | — | US | claimed |
| US-20040259861-A1 | Medicament inhibiting sodium/calcium exchange system | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | claimed |
| CN-1496261-A | Remedies and/or preventives for diabetic ischemic heart diseases | 三菱制药株式会社 | 2004-05-12 | — | — | CN | claimed |
| EP-1409080-A1 | MEDICAMENT INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | Mitsubishi Pharma Corporation (JP) | 2004-04-21 | — | — | EP | claimed |
| EP-1374868-A1 | REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES | Mitsubishi Pharma Corporation (JP) | 2004-01-02 | — | — | EP | claimed |
| CN-1434724-A | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-08-06 | — | — | CN | claimed |
| US-20030114427-A1 | Remedies and/or preventives for nervous system disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-06-19 | — | — | US | claimed |
| WO-2003009897-A1 | MEDICAMENT INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | MITSUBISHI PHARMA CORPORATION (JP) | 2003-02-06 | — | — | WO | claimed |
| EP-1249245-A1 | REMEDIES AND/OR PREVENTIVES FOR NERVOUS SYSTEM DISORDERS | Mitsubishi Pharma Corporation (JP) | 2002-10-16 | — | — | EP | claimed |
| EP-0390654-B1 | Aminobenzenesulfonic acid derivative | MITSUBISHI CHEM IND (JP) | 1994-11-09 | — | — | EP | claimed |
| US-5053409-A | Calcium chanel blockers, antiischemic agent | MITSUBISHI KASEI CORPORATION (JP) | 1991-10-01 | — | — | US | claimed |
| EP-0390654-A1 | Aminobenzenesulfonic acid derivative | Mitsubishi Chemical Corporation (JP) | 1990-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259861-A1 | Medicament inhibiting sodium/calcium exchange system | ATP2A1, ATP2A3, ATP2A2 | USP2 4362/4885HTR6 631/4885ADRB1 226/4885 |
| US-20070270409-A1 | Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease | FABP3, TNNI3, TNNT2 | USP2 3096/4885HTR6 1739/4885ADRB1 139/4885 |
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | SLC5A1, FABP3, IAPP | USP2 3424/4885HTR6 1339/4885ADRB1 42/4885 |
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | ATP2A1, ATP2A2, ATP2A3 | USP2 3382/4885HTR6 3678/4885ADRB1 1151/4885 |
| US-20050004139-A1 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient | SI, NPPA, ATP6V1B1 | USP2 3454/4885HTR6 520/4885ADRB1 122/4885 |
| US-20030114427-A1 | Remedies and/or preventives for nervous system disorders | CHERP, ATP2A1, ATP2A3 | USP2 2900/4885HTR6 1203/4885ADRB1 2184/4885 |
| US-20060167013-A1 | Inhibitors for excessive accumulation of sodium ion in cells | TNNI3, ATP2A1, SLC8B1 | USP2 3548/4885HTR6 3535/4885ADRB1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.